2. Academic Validation
  3. Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia

  • Bioorg Med Chem. 2022 Sep 15:70:116937. doi: 10.1016/j.bmc.2022.116937.
Ji-Bo Kang 1,  Lu Chen 1,  Xue-Jiao Leng 1,  Jing-Jing Wang 1,  Yang Cheng 1,  Shi-Han Wu 1,  Yi-Yuan Ma 1,  Li-Jin Yang 1,  Yu-Hao Cao 1,  Xiao Yang 1,  Zhen-Jiang Tong 1,  Jia-Zhen Wu 1,  Yi-Bo Wang 1,  Hai Zhou 1,  Jia-Chuan Liu 1,  Ning Ding 1,  Wei-Chen Dai 1,  Yan-Cheng Yu 1,  Xin Xue 1,  Shan-Liang Sun 1,  Xiao-Bin Dai 1,  Liang Chang 2,  Xiao-Long Wang 3,  Nian-Guang Li 4,  Zhi-Hao Shi 5
Affiliations

Affiliations

  • 1 National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China.
  • 2 National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: changliang@njucm.edu.cn.
  • 3 National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: gregwang@njucm.edu.cn.
  • 4 National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China. Electronic address: linianguang@njucm.edu.cn.
  • 5 Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China. Electronic address: 1020071799@cpu.edu.cn.
PMID: 35863236 DOI: 10.1016/j.bmc.2022.116937
Abstract

Fms-like tyrosine kinase 3 (FLT3) mutation has been strongly associated with increased risk of relapse, and the irreversible covalent FLT3 inhibitors had the potential to overcome the drug-resistance. In this study, a series of simplified 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine derivatives containing two types of Michael acceptors (vinyl sulfonamide, acrylamide) were conveniently synthesized to target FLT3 and its internal tandem duplications (ITD) mutants irreversibly. The kinase inhibitory activities showed that compound C14 displayed potent inhibition activities against FLT3 (IC50 = 256 nM) and FLT3-ITD by 73 % and 25.34 % respectively, at the concentration of 1 μM. The antitumor activities indicated that C14 had strong inhibitory activity against the human acute myeloid leukemia (AML) cell lines MOLM-13 (IC50 = 507 nM) harboring FLT3-ITD mutant, as well as MV4-11 (IC50 = 325 nM) bearing FLT3-ITD mutation. The biochemical analyses showed that these effects were related to the ability of C14 to inhibit FLT3 signal pathways, and C14 could induce Apoptosis in MV4-11 cell as demonstrated by flow cytometry. Fortunately, C14 showed very weak potency against FLT3-independent human cervical Cancer cell line HL-60 (IC50 > 10 μM), indicating that it might have no off-target toxic effects. In light of these data, compound C14 represents a novel covalent FLT3 kinase inhibitor for targeted therapy of AML.

Keywords

Acute myeloid leukemia; Covalent inhibitor; Fms-like tyrosine kinase; Michael acceptor; Structure-activity relationship.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z